Advancing Atopic Dermatitis Research: Prisys Biotech's Non-Human Primate (NHP) Model

Introduction: Addressing the Challenges of Atopic Dermatitis Drug Development

Atopic Dermatitis (AD) is a chronic inflammatory skin disease affecting millions worldwide. Its complex etiology and diverse symptomatology present significant challenges for novel drug development. To accelerate the creation of innovative therapies, preclinical models that accurately reflect human disease characteristics are indispensable. Prisys Biotech has developed a highly reliable Non-Human Primate (NHP) Atopic Dermatitis model, providing a robust platform for advancing AD research.

In the realm of inflammation and immunology research, NHP models are highly favored due to their close physiological and immunological similarities to humans. Particularly in dermatological research, the skin structure and immune system of NHPs closely mirror those of humans, enabling a more authentic simulation of the complex pathological processes underlying human Atopic Dermatitis. This allows NHP models to provide more accurate assessments of drug efficacy, mechanisms of action, and safety, thereby offering invaluable insights for drug development.

Prisys Biotech has established a mature and stable NHP disease model platform, which includes a robust Atopic Dermatitis model specifically designed to support the preclinical research of therapeutic drugs for AD. Our AD model is based on ovalbumin (OVA) induction, combining systemic sensitization with local challenge to effectively mimic the key pathophysiological features of human AD.

Overview of Experimental Design:

Animal Selection: Adult Cynomolgus Macaques (Macaca fascicularis)

Model Induction: This involves multiple weeks of systemic sensitization followed by subsequent local skin challenges. Sensitization is achieved through injections of OVA combined with an adjuvant and lipopolysaccharide (LPS). Skin challenges are performed on specific skin areas, involving local OVA application after disruption of the skin barrier.

Key Evaluation Endpoints:

1. AI-Powered 3D Behavioral Analysis System: Quantitative Observation of NHP Behavior

Prisys Biotech utilizes an advanced AI-driven 3D behavioral analysis system for NHPs – BehaviorAtlas. This system accurately quantifies and classifies animal behaviors, providing objective and reliable data for drug efficacy assessment.

Core Advantages of the AI 3D Behavioral Analysis System:

• Markerless Design: Avoids interference with the cynomolgus macaques, ensuring animals exhibit natural behaviors for more accurate research outcomes.
• High-Precision 3D Tracking: Employs high-speed cameras and deep learning algorithms to precisely reconstruct the macaque's skeleton and track key body points, achieving superior accuracy.
• Automated Analysis: AI algorithms automatically track key points and analyze behavioral sequences, significantly reducing manual analysis time and potential errors.
• In the Atopic Dermatitis model, BehaviorAtlas precisely quantifies pruritic behaviors, such as the frequency and duration of scratching. By analyzing this data, Prisys Biotech can more accurately assess the anti-pruritic effects of test compounds and analyze activity patterns and behavioral sequences, providing crucial information for safety assessment.

2. Other Critical Assessment Parameters

In addition to the behavioral data provided by BehaviorAtlas, Prisys Biotech employs the following comprehensive evaluation metrics:

• Skin Condition Assessment: Observation and scoring of skin symptoms such as erythema (redness), edema (swelling), exudation, and scaling.

• Skin Barrier Function Evaluation: Measurement of transepidermal water loss (TEWL) to assess skin barrier integrity.
• Physiological Parameter Monitoring: Monitoring of body weight, hematological parameters, and other relevant physiological indicators.
• Histopathological Analysis: Examination of skin tissue biopsies to observe inflammatory cell infiltration and other pathological changes.

• Immunological Analysis: Detection of immune cells and relevant molecules in blood and skin tissue to evaluate treatment effects.

Prisys Biotech's NHP Atopic Dermatitis model offers highly efficient and reliable support for AD drug development, characterized by its high disease relevance, comprehensive evaluation system, and leading technological platform. The model closely mimics human AD in terms of pathophysiology and immunological features. Combined with the precise data from our AI 3D behavioral analysis system, it enables a multi-dimensional assessment of drug efficacy.

Advancements in Atopic Dermatitis drug development necessitate scientifically rigorous preclinical models. Prisys Biotech's Non-Human Primate Atopic Dermatitis model, with its high fidelity to human disease characteristics, comprehensive evaluation system, and advantages in advanced technologies like the AI 3D behavioral analysis system, provides robust support for AD drug discovery and translational medicine research.

Contact Us:

To learn more about Prisys Biotech's models and services, please visit our website at www.prisysbiotech.com, or contact our business development team at bd@prisysbiotech.com / +86-21-50435616.

About Prisys Biotech

Prisys Biotechnologies Co., Ltd. is a "High-Tech Enterprise" and a "Shanghai Specialized, Refined, Special, and New SME," fully accredited by AAALAC International. The company is dedicated to becoming a leader in large animal pharmacology and efficacy studies, specializing in disease model development, pharmacology and efficacy research, safety assessment, biomarker analysis, and mechanism of action/proof-of-concept studies, primarily utilizing Non-Human Primates (cynomolgus macaques) and other experimental animals.

Prisys Biotech has established high-standard R&D platforms aligned with pharmaceutical industry standards in the field of translational medicine, capable of providing scientifically rigorous experimental support and data services for new drug development. The company has fostered long-term collaborations with top domestic and international pharmaceutical companies, biotechnology firms, and academic institutions, contributing to the advancement of drug development through innovative technology, professional expertise, and high-quality service.